Abridge, a Pittsburgh-based generative AI platform for clinical conversations, has secured $250 million in Series D funding, led by Elad Gil and IVP. Other significant investors include Bessemer Venture Partners, California Health Care Foundation, and CVS Health Ventures. This investment aims to enhance AI capabilities and foster commercial growth for broader applications in healthcare. Founded in 2018, Abridge is designed to alleviate bureaucratic burdens in health systems, enabling clinicians to prioritize patient care while improving documentation efficiency. The platform supports clinicians across various specialties and is available in over 28 languages.